OptiNose (OPTN) Projected to Post Quarterly Earnings on Thursday

OptiNose (NASDAQ:OPTN) is expected to announce its earnings results before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.67) per share and revenue of $21.02 million for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

OptiNose Stock Performance

OPTN opened at $5.80 on Wednesday. The firm has a market cap of $58.35 million, a P/E ratio of -1.38 and a beta of -0.30. The business has a 50 day moving average price of $5.80 and a 200 day moving average price of $8.23. OptiNose has a twelve month low of $4.82 and a twelve month high of $29.65.

Insider Buying and Selling

In related news, CEO Ramy A. Mahmoud sold 6,376 shares of OptiNose stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $5.29, for a total transaction of $33,729.04. Following the sale, the chief executive officer now directly owns 126,931 shares of the company’s stock, valued at $671,464.99. This trade represents a 4.78 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.30% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research firms have issued reports on OPTN. HC Wainwright upped their price target on shares of OptiNose from $5.00 to $18.00 and gave the company a “buy” rating in a report on Friday, January 3rd. Lake Street Capital decreased their target price on OptiNose from $45.00 to $17.00 and set a “buy” rating for the company in a research note on Thursday, January 16th.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.